Mereo BioPharma Group Faces Class Action Lawsuit
Analysis based on 50 articles · First reported Feb 05, 2026 · Last updated Mar 04, 2026
The market is negatively impacted for Mereo BioPharma Group due to the class action lawsuit, potentially leading to a decline in its stock price. For investors who purchased Mereo BioPharma Group ADSs during the Class Period, there is a potential for compensation through the lawsuit.
Rosen Law Firm has reminded investors of the April 6, 2026 lead plaintiff deadline for a class action lawsuit against Mereo BioPharma Group. The lawsuit alleges that Mereo BioPharma Group made false and misleading statements regarding its Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). These statements, which expressed confidence in setrusumab's ability to reduce fracture rates, were allegedly made while concealing that neither study hit its primary endpoints. This led investors to purchase Mereo BioPharma Group's ADSs at artificially inflated prices, resulting in damages when the true details emerged.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard